Journal of Antimicrobial Chemotherapy (2000) 45, 13
© 2000 The British Society for Antimicrobial Chemotherapy
In vitro activity of gemifloxacin against a broad range of recent clinical isolates from the USA
SmithKline Beecham Pharmaceuticals, Collegeville, PA, USA
The antibacterial potencies of gemifloxacin (SB-265805) and 13 comparator compounds were determined by broth microdilution against a panel of 645 Gram-positive and 995 Gram-negative organisms collected from various USA sites. Time–kill studies were performed and postantibiotic effect (PAE) was determined for several organisms using trovafloxacin and ciprofloxacin as comparator compounds. Based on MIC90s, gemifloxacin was the most potent compound tested against Gram-positive isolates: Streptococcus pneumoniae (MIC90 0.016 mg/L), Streptococcus agalactiae (0.03 mg/L), Streptococcus pyogenes (0.03 mg/L), viridans streptococci (0.12 mg/L), methicillin-susceptible Staphylococcus aureus (0.03 mg/L), Staphylococcus epidermidis (2 mg/L), Staphylococcus saprophyticus (0.016 mg/L) and Enterococcus faecalis (2 mg/L). Against Gram-negative isolates, the potency of gemifloxacin was equal to that of levofloxacin and ciprofloxacin and generally better than that of ofloxacin, grepafloxacin, trovafloxacin and nalidixic acid. MIC90s for gemifloxacin were: Haemophilus influenzae (
0.008 mg/L), Moraxella catarrhalis (0.008 mg/L), Escherichia coli (0.016 mg/L), Klebsiella pneumoniae (0.25 mg/L), Klebsiella oxytoca (0.25 mg/L), Enterobacter cloacae (1 mg/L), Enterobacter aerogenes (0.25 mg/L), Proteus spp. (4 mg/L), Serratia spp. (1 mg/L), Citrobacter freundii (2 mg/L), Morganella morganii (0.12 mg/L), Pseudomonas aeruginosa (8 mg/L), Stenotrophomonas maltophilia (4 mg/L) and Acinetobacter spp. (32 mg/L). Gemifloxacin was bactericidal for all organisms studied at 2 and 4 x MIC. The PAE for most strains was in the range 0.7–2.5 h at 2 and 4 x MIC, although longer PAEs were observed with H. influenzae, P. aeruginosa and Proteus vulgaris (>6 h at 4 x MIC) and shorter PAEs with E. faecalis (0.1–0.6 h) and K. pneumoniae (0.1–0.2 h). In conclusion, gemifloxacin is a novel quinolone with a broad spectrum of antimicrobial activity. It has substantially improved potency against Gram-positive organisms, especially streptococci, for which gemifloxacin is generally at least eight- to 16-fold more potent than other quinolones tested. It retains the good Gram-negative activity seen with ciprofloxacin and levofloxacin and shows good bactericidal activity and prolonged PAEs.
* Correspondence address. Microbiology Research, SmithKline Beecham Pharmaceuticals, 1250 S. Collegeville Road, Collegeville, PA 19426-0989, USA. Tel: +1-610-917-6273; Fax: +1-610-917-4617; E-mail: Kenneth_Coleman{at}SBPHRD.com
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  A W Rimoin, H S Hamza, A Vince, R Kumar, C F Walker, R A Chitale, A L A da Cunha, S Qazi, and M C Steinhoff Evaluation of the WHO clinical decision rule for streptococcal pharyngitis Arch. Dis. Child., October 1, 2005; 90(10): 1066 - 1070. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. Y. Tani, L. G. Veasy, L. L. Minich, and R. E. Shaddy Rheumatic Fever in Children Younger Than 5 Years: Is the Presentation Different? Pediatrics, November 1, 2003; 112(5): 1065 - 1068. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. E. Gieseker, M. H. Roe, T. MacKenzie, and J. K. Todd Evaluating the American Academy of Pediatrics Diagnostic Standard for Streptococcus pyogenes Pharyngitis: Backup Culture Versus Repeat Rapid Antigen Testing Pediatrics, June 1, 2003; 111(6): e666 - 670. [Abstract] [Full Text] [PDF]
|
|